Clinical Trials Logo

Breast Neoplasms clinical trials

View clinical trials related to Breast Neoplasms.

Filter by:

NCT ID: NCT04049695 Active, not recruiting - Clinical trials for Cognitive Dysfunction

Improving Cognition After Cancer

ICAN
Start date: September 9, 2019
Phase: N/A
Study type: Interventional

This study will test whether a physical activity intervention can improve cognition in breast cancer survivors and help the development of physical activity guidelines for cognition in breast cancer survivors.

NCT ID: NCT04040569 Active, not recruiting - Breast Cancer Clinical Trials

A Phase I Dose Escalation Study of Single Fraction Ablative Pre-operative Partial Breast (S-PBI) for Early Stage Breast Cancer

Start date: December 25, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this phase I trial is to evaluate dose-limiting toxicity while dose escalating single-fraction preoperative S-PBI to a presumed radioablative dose over 3 cohorts, starting with 30Gy in 1 fraction and advancing to 34Gy and 38Gy in 1 fraction.

NCT ID: NCT04024800 Active, not recruiting - Clinical trials for Triple-negative Breast Cancer

Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer

NSABP FB-14
Start date: May 3, 2019
Phase: Phase 2
Study type: Interventional

This study will look to establish the recommended biologic dose of AE37 in combination with pembrolizumab that will enhance the tumor-specific immune response and demonstrate efficacy in patients with advanced triple-negative breast cancer. This study will take place in two parts. Stage 1 will be the safety cohort (13 patients) to determine the recommended dose of AE37 vaccine that can safely be administered with pembrolizumab. Stage 2 will be an expansion cohort (16 patients) that will consist of the recommended dose of AE37 determined in Stage 1.

NCT ID: NCT04024462 Active, not recruiting - Clinical trials for HER2-positive Early Breast Cancer

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

Start date: February 5, 2020
Phase: Phase 3
Study type: Interventional

This study will evaluate the pharmacokinetics, efficacy, and safety of the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) as compared with those of the pertuzumab intravenous (IV) and trastuzumab IV formulations in Chinese participants with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.

NCT ID: NCT04024436 Active, not recruiting - Clinical trials for Metastatic Breast Cancer

A Study of TAS-120 in Patients With Metastatic Breast Cancer

Start date: August 30, 2019
Phase: Phase 2
Study type: Interventional

The purpose of the trial is to evaluate a patient's response to a Fibroblast Growth Factor Receptor (FGFR) inhibitor, futibatinib (TAS-120), used either alone or in combination with the hormonal therapy, fulvestrant. This study will be conducted in patients with metastatic breast cancer who have specific Fibroblast Growth Factor Receptor gene abnormalities and who have previously received conventional therapies to treat their breast cancer, or who are not able to tolerate certain cancer therapies. This study will also evaluate the safety of taking futibatinib, or futibatinib and fulvestrant, by learning about the potential side effects.

NCT ID: NCT04023110 Active, not recruiting - Breast Cancer Clinical Trials

Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab

CCTGuide Pilot
Start date: August 9, 2019
Phase: Phase 1
Study type: Interventional

Investigators will evaluate the safety, tolerability, and feasibility of a risk-guided cardioprotective treatment strategy with carvedilol, as compared to usual care, in breast cancer patients undergoing treatment with doxorubicin, trastuzumab, or the combination.

NCT ID: NCT04021069 Active, not recruiting - Breast Cancer Clinical Trials

Using Clinicopathomic Markers to Predict Neoadjuvant Chemotherapy Response in Breast Cancer

Start date: August 30, 2018
Phase:
Study type: Observational

This study examines retrospective clinical data on patients diagnosed with breast cancer and monitor their response to neoadjuvant chemotherapy, incidence of locoregional recurrence, distant metastasis, and disease-free survival. The hypothesis of this study is that breast cancer patients who achieve a pathological complete response (pCR) to neoadjuvant chemotherapy demonstrate distinct clinicopathomic biomarker signatures.

NCT ID: NCT04016376 Active, not recruiting - Breast Cancer Clinical Trials

Study of Nerve Block Pain Management in Patients Undergoing a Double Mastectomy With Immediate Reconstruction

Start date: July 5, 2019
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine if the injection site or sites used for administering pain medication (nerve blocks) before a double mastectomy with immediate reconstruction with tissue expanders reduce the need for pain medication after surgery.

NCT ID: NCT04014283 Active, not recruiting - Breast Neoplasms Clinical Trials

Prevention of Female Cancers by Optimization of Selenium Levels in the Organism.

SELINA
Start date: October 2014
Phase: N/A
Study type: Interventional

Hypothesis to be tested: Oral supplementation or diet modifications of selenium to a specified range will be effective in reducing the risk of developing cancer of any type in women with high risk of breast cancer, as compared to placebo.

NCT ID: NCT04007770 Active, not recruiting - Gynecologic Cancer Clinical Trials

Acupuncture Pilot Study for Cancer-related Cognitive Function

Start date: July 1, 2019
Phase: Phase 2
Study type: Interventional

This study is being done to explore whether acupuncture can improve cognitive difficulties in patients diagnosed with cancer.